



**Department of Defense
US Army Medical Research
and Materiel Command**



**Fiscal Year 2004 (FY04)
Prostate Cancer Research Program (PCRP)
Funded Awards List**

TABLE OF CONTENTS

Introduction

Research Awards

- ◆ Clinical Trial Development
- ◆ Exploration-Hypothesis Development
- ◆ Exploration-Resource Development
- ◆ Historically Black Colleges and Universities (HBCU)
Collaborative Partnership
- ◆ Health Disparity Research-Prostate Scholar
- ◆ Idea Development
- ◆ New Investigator

Training Awards

- ◆ HBCU Undergraduate Collaborative Summer Training
Program
- ◆ Health Disparity Training-Prostate Scholar
- ◆ Physician Research Training
- ◆ Postdoctoral Traineeship

Participants

- ◆ Peer Reviewers
- ◆ Integration Panel Members
- ◆ Ad Hoc Programmatic Reviewers

Glossary of Terms

Introduction

The US Army Medical Research and Materiel Command (USAMRMC) is pleased to present the awards list of funded projects for the fiscal year 2004 (FY04) Prostate Cancer Research Program (PCRP). Award negotiations were completed on September 30, 2005. The awards listed in this document were selected in a competitive, two-tier review process. Funding decisions were based on evaluations of scientific excellence in the first tier, followed by determinations of programmatic relevance in the second tier. These projects represent a diverse portfolio of scientific research in two categories: (1) Research Awards, and (2) Training Awards.

Congressional direction for FY04 specified \$85 million for prostate cancer research. Following the receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, award recommendations were made, and contract negotiations were completed. A total of 223 awards was made.

The FY04 programmatic strategy called for proposals in prostate cancer research through eleven program announcements released between early November 2003 and late January 2004. The Research Award category included six award mechanisms: Clinical Trial Development, Exploration – Research Development, Exploration – Hypothesis Development, Health Disparity Research – Prostate Scholar, New Investigator, and Idea Development Awards. The Clinical Trial Development Award was designed to support the establishment of collaborations and development of clinical protocols to provide a foundation for investigator-initiated clinical trials. The Exploration – Hypothesis Development Award was designed to provide funds to support initial exploration of innovative, untested, and potentially groundbreaking concepts in prostate cancer. Exploration – Resource Development Awards support product-driven research aimed at developing critical resources needed to advance prostate cancer research. These resources may include, but are not limited to, development of animal models, cell lines, and reagents. Health Disparity Research – Prostate Scholar Awards are intended to encourage scientists or physicians who have postdoctoral and/or fellowship training, but are not yet established researchers, to focus their research efforts on the disparate burden of prostate cancer in African Americans. New Investigator Awards are targeted to investigators within six years of their last fellowship or postdoctoral position who have innovative ideas and new technologies applicable to prostate cancer research and treatment. Idea Development Awards are aimed at giving established prostate cancer investigators and investigators who want to move into prostate cancer research and who have preliminary data relevant to prostate cancer the necessary support and time to conduct under-investigated areas of research. Idea Development Awards are designed to encourage innovative approaches to prostate cancer research from established investigators who are at, or above, the assistant professor level, or equivalent, and to assist an investigator to continue the pursuit of, or enter into, prostate cancer research.

The Training Award category consists of five award mechanisms: Postdoctoral Traineeship, Health Disparity Training – Prostate Scholar, Historically Black Colleges and Universities (HBCU) Collaborative Partnership, HBCU Undergraduate Collaborative Summer Training Program, and Physician Research Training Awards. Postdoctoral Traineeship Awards provide support for recent doctoral degree graduates to gain experience in prostate cancer research.

Health Disparity Training – Prostate Scholar Awards are intended to provide investigators in the early stages of their careers with mentored training opportunities that focus on the disparate burden of prostate cancer in African Americans. The HBCU Collaborative Partnership Awards are directed at HBCU as a means to increase the number of HBCU scientists trained as prostate cancer researchers by establishing stable, long-term partnerships between an applicant HBCU and a collaborating non-HBCU institution. The HBCU Undergraduate Collaborative Summer Training Program Award is intended to establish summer training programs at host institutions that will provide meaningful prostate cancer research experiences for HBCU undergraduate students. The Physician Research Training Award mechanism addresses the critical shortage of physicians performing prostate cancer research and fosters their training toward becoming independent researchers. The award is designed to provide a mentored training experience for physicians who are in the last year of graduate medical education or fellowships, or within the first three years of their appointment as an assistant professor or equivalent.

As the funded investigators embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientific, clinical, and consumer advisors. The expertise, vision, and diversity of perspective of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons affected by prostate cancer. It is with great anticipation and excitement that we await the outcomes of this body of research.

Clinical Trial Development Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040903	Stadler	Walter	The University of Chicago	Androgen Replacement as Treatment for Hormone Refractory Prostate Cancer	\$100,000
PC040944	Valicenti	Richard	Thomas Jefferson University	A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-153 in Localized, High-Risk, Prostate Cancer	\$99,761
PC041175	Hart	Derek	Mater Medical Research Insititute	A Phase 1 Clinical Trial of a Novel Blood Dendritic Cell Preparation for the Immunotherapy of Prostate Cancer	\$99,861
PC041181	Kurdziel	Karen	Virginina Commonwealth University	Multimodality Image-Guided HDR/IMRT in Prostate Cancer: Combined Molecular Targeting Using Nanoparticle MR, 3D MRSI, and 11C Acetate PET Imaging	\$99,505
PC041195	Botchkina	Galina	State University of New York, Stony Brook	Validation of Quantitative Multimodality Analysis of Telomerase Activity in Urine Cells as a Noninvasive Diagnostic and Prognostic Tool for Prostate Cancer	\$63,444
PC041199	Deisseroth	Albert	Sidney Kimmel Cancer Center	Adjuvant Immunotherapy for Patients at High Risk of Recurrence Following Radiation Therapy for Prostate Cancer	\$100,000
PC041201	McNeel	Douglas	University of Wisconsin Comprehensive Cancer Center	Augmentation of Cytolytic (gamma) (delta) T Cells as a Novel Treatment for Prostate Cancer	\$84,536

Exploration - Hypothesis Development Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040014	Rettig	Matthew	VAGLAHS-West LA	Inhibition of Androgen Receptor Binding to the Androgen Response Element as a Therapeutic Strategy for Androgen-Independent Prostate Cancer	\$92,250
PC040030	O'Keefe	Denise	University of Pittsburgh	Targeted Chromatin Remodeling Therapy for Androgen Independent Prostate Cancer	\$111,361
PC040089	Douglas	Joanne	University of Alabama at Birmingham	A Dual-Action Armed Replicating Adenovirus for the Treatment of Osteoblastic Bone Metastases of Prostate Cancer	\$108,750
PC040286	Nor	Jacques	Regents of the University of Michigan	Small Molecule Inhibitors of Bcl-2/Bcl-xL and Prostate Tumor Angiogenesis	\$114,352
PC040298	Hu	Chien-An	University of New Mexico School of Medicine	Mutations in PUMA Gene Cause Prostate Cancer Development and Aggressiveness	\$92,723
PC040408	Rinker-Schaeffer	Carrie	University of Chicago	Post-Transcriptional Regulation of MKK4 – A Stress Signaling Kinase Implicated in the Regulation of Metastatic Growth	\$110,595
PC040477	Beer	Tomasz	Oregon Health & Science University	A Novel Vitamin D Target in Human Prostate Cancer	\$113,163
PC040535	Cui	Yan	Louisiana State University Health Sciences Center	Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cell	\$106,493
PC040545	Griffith	Jeffrey	University of New Mexico Health Sciences Center	Prognostic Value of Allelic Imbalance in Prostate Biopsy	\$112,422
PC040561	Oshima	Robert	The Burnham Institute	Is Prostate Cancer Dependent on Notch Signaling?	\$143,250
PC040626	Ke	Youqiang	Liverpool University	Identification of Possible Molecular Markers to Predict the Malignant Tendency of the Prostate Intraepithelial Neoplasia (PIN) Lesions	\$105,241
PC040655	Peehl	Donna	Stanford University	Origin of Prostate Cancer-Associated Stroma: Epithelial Mesenchymal Transition (EMT)	\$120,000
PC040672	Nordeen	Steven	University of Colorado Health Sciences Center	HOXC5 as a Biomarker of Disease Presence in Tumor-Associated Normal Prostate	\$115,500
PC040763	Zehner	Zendra	Virginia Commonwealth University	Novel Role of Vimentin's Regulatory Proteins in Prostate Tumor Metastasis	\$112,500

PC040785	Roselli	Charles	Oregon Health and Sciences University	Effect of Saw Palmetto on the Development and Progression of Prostate Carcinoma in TRAMP Mice	\$113,248
PC040790	Mossman	Karen	McMaster University	Molecular Characterization of Prostate Cancer Cell Oncolysis by Herpes Simplex Virus ICP0 Mutants	\$83,877
PC040796	Latini	David	University of California, San Francisco	Psychosocial and Patient Education Needs of Prostate Cancers Selecting Watchful Waiting	\$98,732
PC040802	Srivastava	Rakesh	University of Maryland	Regulation of FOXO Transcription Factors and Apoptosis by Curcumin in Prostate Cancer Prevention	\$111,375
PC040844	Grishina	Irina	New York University School of Medicine	The Role of Notch Signaling in Cell Fate Choice in the Prostate	\$126,750
PC040861	Wu	Jie (Jerry)	H. Lee Moffitt Cancer Center and Research Institute	A Novel Approach for Molecular Ablation of Androgen Receptor in Prostate Cancer Cells	\$122,250
PC040873	Yang	Wannian	Geisinger Clinic	Construction of a Mitogenesis-Coupled Apoptosis Molecular Device	\$104,420
PC040879	Baker	David	University of Washington	Battling Hormone Resistant Prostate Cancer with Computationally Designed Protein Therapeutics	\$113,700
PC040911	Hemler	Martin	Dana-Farber Cancer Institute/Harvard Medical School	Examination of CD82 Microdomains in Prostate Cancer	\$128,250
PC040931	Nagle	Dale	University of Mississippi	Marine Natural Products: An Untapped Source of New Drugs for Prostate Cancer	\$107,625
PC040947	deVere White	Ralph	University of California, Davis	Identifying Molecular Targets for Chemoprevention in a Rat Model	\$109,416
PC040948	Stafforini	Diana	University of Utah	Using Genetically Engineered Mice to Probe the Role of Bioactive Lipids in Prostate Carcinogenesis	\$112,125
PC041000	Crawford	E. David	University of Colorado Health Sciences Center	Magnetic Resonance Spectroscopy (MRS) of Prostatic Fluids for Early Detection of Prostate Cancer	\$115,484
PC041017	Prendergast	George	Lankenau Institute for Medical Research	IDO Inhibitors for Combination Therapy of Prostate Cancer	\$118,400
PC041074	Bova	George	Johns Hopkins University	Pilot Comparison of Stromal Gene Expression Among Normal Prostate Tissues and Primary Prostate Cancer Tissues in White and Black Men	\$122,625
PC041086	Lilja	Hans	Sloan-Kettering Institute for Cancer Research	Novel Protein Microarray Technology to Examine Men with Prostate Cancer	\$126,279

PC041125	Wong	Albert	Alteris Therapeutics, Inc.	Rapid Identification of Alternative Splice Forms, a New Source for Tumor Specific Alterations	\$118,500
PC041140	Ames	Bruce	Children's Hospital Oakland Research Institute	Zinc Deficiency and Microtubule Function in Prostate Cells	\$120,075
PC041144	Guo	Peixuan	Purdue University	Phi29 Hexameric Motor pRNA Nanoparticles as Polyvalent Vector for Prostate Cancer Detection and Specific Targeted Gene Delivery	\$113,998

Exploration - Resource Development Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040252	Rhim	Johng	Center for Prostate Disease Research	Development of a Human Cancer Cell Model for the Study of Familial Prostate Cancer	\$112,837
PC040420	Peehl	Donna	Stanford University	Resource Center for Primary Cultures of Human Prostatic Cells and Derived Materials	\$120,000
PC040425	Mishra	Bhubaneswar	New York University	Computational Genomics Tools for Copy-Number Fluctuations in Prostate Cancer	\$109,587
PC040426	Foster	Barbara	Roswell Park Cancer Institute	Development of a Novel Murine Model of Bone Metastasis for Prostate Cancer: TRAMP Cell Lines that Target and Remodel Bone in Immune Intact Hosts	\$127,113
PC040550	van den Ham	Rene	Faculty of Veterinary Medicine, University of Utrecht	Defining Canine Spontaneous Prostate Cancer as a Model for Human Hormone Refractory Prostate Carcinoma Using Comparative Genome Wide Gene Expression Profiling	\$90,000
PC040621	Gololobov	Gennady	University of Texas-Houston Medical School	Antibody-Based Drug Carriers for Targeted Prostate Cancer Chemotherapy	\$111,375
PC040797	Shtutman	Michael	Ordway Research Institute	Generation of Inducible RNAi Expression Library for Target Identification in Prostate Cancer	\$123,750
PC040915	Trifiro	Mark	Jewish General Hospital	Development of a Transgenic Mouse Model to Investigate the Role of the Androgen Receptor and its CAG Repeat in Human Prostate Cancer	\$89,511
PC041038	Bova	George	Johns Hopkins University	Proof of Concept for Systematic Collection of Optimal Molecular Quality Anatomically Oriented Normal Prostate from Diverse Age and Race Transplant Donors	\$122,625

HBCU Collaborative Partnership Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040907	Howard	Daniel	Shaw University	The Shaw UNC-CH Center for Prostate Cancer Research (SUCPCR)	\$852,263
PC041176	Ukoli	Flora	Meharry Medical College	Development of the Meharry Medical College Prostate Cancer Research Program	\$815,865

Health Disparity Research - Prostate Scholar Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040021	Osman	Iman	New York University School of Medicine	Biologic Basis of Racial Disparity of Prostate Cancer	\$443,367
PC040055	Rennert	Hanna	University of Pennsylvania Health System	Analysis of RNASEL, MSR1, and ELAC2 Genes in Prostate Cancer Risk in African American and Asian-Indian Men: A Disparity Study	\$475,500
PC040117	Daniels	Nicholas	University of California, San Francisco	Reduction of Racial Disparities in Prostate Cancer	\$453,496
PC040203	Denberg	Thomas	University of Colorado Health Sciences Center	Patient Race and Outcome Preferences as Predictors of Urologists' Treatment Recommendations and Referral Patterns in Early-Stage Prostate Cancer	\$461,997
PC040735	Taylor	Teletia	Howard University	Short-Term Exercise and Prostate Cancer Prevention in African American Men	\$421,943

Idea Development Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040002	Xu	H. Eric	Van Andel Research Institute	Structure and Function of Androgen Receptor in Prostate Cancer	\$656,250
PC040013	Fedarko	Neal	Johns Hopkins University	Prostate Cancer Progression and Serum SIBLING (Small Integrin Binding N-linked Glycoprotein) Levels	\$611,948
PC040121	Yeh	Edward	University of Texas M.D. Anderson Cancer Center	Role of SENP1 in Prostate Cancer Development	\$566,250
PC040160	Coetzee	Gerhard	University of Southern California	Androgen Receptor-Mediated Escape Mechanisms from Androgen Ablation Therapy	\$610,313
PC040161	Evans	Christopher	University of California, Davis	Castration-Induced Neuroendocrine Mediated Progression of Prostate Cancer	\$552,174
PC040198	Hsieh	Chia-Ling	Emory University	Gene-Based Molecular Targeting of Tumor-Endothelium Interaction for the Treatment of Human Prostate Cancer Bone Metastasis	\$573,750
PC040204	Chan	June	University of California, San Francisco	Diet, Exercise, Quality of Life, and Prostate Cancer Progression in a Large Cohort of Men with Prostate Cancer	\$568,125
PC040215	Duckett	Colin	Regents of the University of Michigan	XIAP as a Molecular Target for Therapeutic Intervention in Prostate Cancer	\$516,299
PC040221	Languino	Lucia	University of Massachusetts Medical School	In Vitro and in Vivo Modulation of Prostate Cancer Cell Proliferation by Integrins and Type 1 Insulin-Like Growth Factor Receptor	\$596,250
PC040238	Trump	Donald	Roswell Park Cancer Institute	Evaluation of CYP24 as a Target for Enhancing Vitamin D Analogue Activity in Prostate Cancer: Preclinical and Clinical Studies	\$687,801
PC040240	Kaaks	Rudolf	International Agency for Research on Cancer	Genetic Variation in the Mtor Pathway and Prostate Cancer Risk: A Study Within the European Prospective Investigation Into Cancer and Nutrition (Epic)	\$421,878
PC040246	Balk	Steven	Beth Israel Deaconess Medical Center	AR-NCoR Interaction as a Therapeutic Target for Prostate Cancer Prevention and Treatment	\$637,500
PC040256	Gelman	Irwin	Roswell Park Cancer Institute	High Throughput Screen to Identify Novel Drugs that Inhibit Prostate Cancer Metastasis	\$613,290
PC040260	Chung	Leland	Emory University	Molecular Imaging with Quantum Dots Probing EMT and Prostate Cancer Metastasis in Live Animals	\$573,750
PC040264	Dudouet	Brigitte	Sidney Kimmel Cancer Center	Vascular Targeting of Spontaneous Prostate Cancer with Dendritic Cell-Based Vaccine	\$650,275
PC040277	Bubley	Glenn	Beth Israel Deaconess Medical Center	Effect of a HIF-1 Alpha Polymorphism on the Incidence and Severity of Prostate Cancer	\$351,397

PC040282	Xing	Lei	Stanford University School of Medicine	Prostate Dose Escalation by a Innovative Inverse Planning-Driven IMRT	\$600,001
PC040299	Alaoui-Jamali	Moulay	SMBD Jewish General Hospital	The Cell-Cell Communication Network in Prostate Cancer: Molecular Studies and Identification of Targets for Therapeutic Intervention	\$546,894
PC040311	DiPaola	Robert	The Cancer Institute of New Jersey	The Effect of Glycolytic Modulation on Prostate Cancer	\$583,125
PC040315	Zhou	Wei	Emory University School of Medicine	Disease Progression in Patients with 8p Allelic Imbalance Prostate Tumors	\$383,176
PC040321	Ghosh	Jagadananda	Henry Ford Health System	Selenium Molecular Regulation in Prostate Cancer Apoptosis	\$540,000
PC040322	Frenkel	Baruch	University of Southern California	Target Genes for the Androgen Receptor in Prostate Cancer	\$610,213
PC040323	Vieweg	Johannes	Duke University Medical Center	Enhancement of Anti-Telomerase Immunity Against Prostate Cancer	\$502,046
PC040341	Guisse	Theresa	University of Virginia	Preclinical Evaluation of Serine/Threonine Kinase Inhibitors Against Prostate Cancer Metastases	\$571,521
PC040344	Ragupathi	Govind	Memorial Sloan-Kettering Cancer Center	Construction of Prostate Specific Membrane Antigen (PSMA)-KLH Conjugate Vaccine for use in a Prime Boost Strategy with a PSMA DNA Vaccine	\$600,862
PC040358	Xu	Yang	University of California, San Diego	Functional Analysis of p53 Mutants Selected for in Prostate Cancer	\$569,913
PC040364	Plymate	Stephen	Harborview Medical Center	Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR)	\$556,504
PC040366	Fukuda	Michiko	The Burnham Institute	Role of Tastin in Prostate Cancer	\$716,250
PC040371	Bogen	Kenneth	Lawrence Livermore National Laboratory	PSA-Based Screening Outcomes, Dietary Heterocyclic Amine Exposure, and Prostate Cancer Risk in African Americans	\$597,519
PC040436	van Golen	Kenneth	Regents of the University of Michigan	Mechanism of Action of Ac-PSCN-NH ₃ , a Novel Compound that Inhibits Prostate Cancer Recurrence and Metastasis	\$570,038
PC040455	Zhang	Jian-Ting	Indiana University School of Medicine	The Double-Edged Sword of Prostate Cancer: 14-3-3(σ)	\$564,375
PC040460	Hayward	Simon	Vanderbilt University Medical Center	A Myc-Driven in Vivo Model of Human Prostate Cancer	\$566,250
PC040486	Ittmann	Michael	Baylor College of Medicine	Fibroblast Growth Factor Receptor-4 and Prostate Cancer Progression	\$563,873
PC040498	Roberts	Charles	Oregon Health & Science University	A Novel Mechanism of Androgen Receptor Action	\$556,221

PC040500	Chen	Ching-Shih	The Ohio State University	Novel Molecularly Targeted Agents for Prostate Cancer Treatment	\$560,625
PC040502	Batra	Surinder	University of Nebraska	Molecular Studies on MIC1/PDF in Human Prostate Cancer	\$551,251
PC040520	Rosenfeld	Michael	University of California, San Diego	Strategies for Preventing Hormone-Resistance in Prostate Cancer	\$570,000
PC040537	Wang	Shaomeng	Regents of the University of Michigan	Preclinical Testing the Therapeutic Potential of a Potent and Novel Small-Molecule Inhibitor of Bcl-2 as a Novel Therapy for Hormone-Refractory Prostate Cancer	\$561,018
PC040566	Vallabhajosula	Shankar	Weill Medical College of Cornell University	Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel	\$630,000
PC040572	Mousses	Spyro	Translational Genomics Research Institute	Validation of the Role of S100P in Growth and Survival of Hormone Refractory Prostate Cancer	\$609,669
PC040619	Van Dyke	Terry	University of North Carolina at Chapel Hill	Novel Techniques for Exploring the Underlying Genetic Mechanisms of Prostate Cancer	\$543,361
PC040635	Lilly	Michael	Loma Linda University	Pim-1: A Molecular Target to Modulate Cellular Resistance to Therapy in Prostate Cancer	\$600,210
PC040705	George	Daniel	Duke University	Molecular and Pathologic Effects of mTOR Inhibition in Patients with Metastatic Hormone-Refractory Prostate Cancer	\$469,460
PC040706	Piedrafita	F. Javier	Sidney Kimmel Cancer Center	Identification of Novel Retinoid Targets in Prostate Cancer	\$682,295
PC040715	Rubin	Mark	Brigham and Women's Hospital/Harvard Medical School	Identification of Aggressive Prostate Cancer Using SNP Analysis	\$517,203
PC040737	Fenton	Bruce	University of Rochester Medical Center	Potential of Prostate Cancer Radiotherapy Using Combined Antiangiogenic and Antitumor Therapies	\$589,228
PC040747	Luo	Jun	Johns Hopkins Medical Institutions	Myosin VI Underlies Human Prostate Cancer Invasion	\$611,405
PC040758	Nanus	David	Weill Medical College of Cornell University	Anti-Angiogenic Action of Neutral Endopeptidase	\$630,000
PC040768	Sadar	Marianne	British Columbia Cancer Agency	Discovery of New Drug Candidates for the Prevention of Hormone Refractory Prostate Cancer	\$405,000
PC040777	Schaufele	Fred	University of California, San Francisco	Temporal and Spatial Dynamics of Androgen Receptor Conformation and Interactions in Prostate Cancer Cells	\$568,125
PC040780	Gardiner	Robert	University of Queensland	Development of a Novel, Non-Invasive Diagnostic Test for Prostate Cancer	\$516,360

PC040795	Godley	Paul	University of North Carolina at Chapel Hill	A Case-Control Study of Prostate Cancer Screening among African American and Caucasian Medicare Recipients	\$485,883
PC040835	Xiong	Yue	University of North Carolina at Chapel Hill	Suppression of Prostate Tumors by INK4c and PTEN	\$546,632
PC040836	Thomas	Michael	The Regents of the University of California	A Novel Assay of Citrate, Choline, and Spermine in Prostate Cancer in Vivo	\$523,909
PC040838	Selander	Katri	University of Alabama at Birmingham	MIC-1 in Prostate Cancer Bone Metastases	\$496,781
PC040845	Kung	Hsing-Jien	University of California, Davis Cancer Center	Characterization of an Androgen-Induced and Activated Protein Kinase	\$564,687
PC040854	Birkett	Nicholas	University of Ottawa	Dietary Heterocyclic Amines and Polymorphic Variants in the Etiology of Prostate Cancer	\$513,638
PC040872	Platz	Elizabeth	Johns Hopkins Bloomberg School of Public Health	Telomere Length as a Predictor of Aggressive Prostate Cancer	\$589,185
PC040878	Talcott	James	Harvard Medical School/Massachusetts General Hospital	Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer	\$585,381
PC040892	Reiter	Robert	University of California, Los Angeles	Reg IV: A Candidate Marker of Metastatic Hormone Refractory Prostate Cancer	\$479,159
PC040912	Dodd	Janice	University of Manitoba	In Vivo Activity of Insulin-Like Growth Factor Binding Protein-3 in Prevention of Prostate Cancer Progression	\$436,797
PC040921	Malkovsky	Miroslav	University of Wisconsin-Madison	Therapeutic Activations of (gamma delta) T Cells in Prostate Cancers	\$545,625
PC040961	Levine	Alice	Mount Sinai School of Medicine	Effect of COX-2 (PGE2) and IL-6 on Prostate Bone Metastases	\$635,625
PC040971	Oh	Youngman	Virginia Commonwealth University	Dysregulation of the Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) and IGF1 Receptor Axis in Prostate Tumorigenesis	\$562,480
PC040973	Cramer	Scott	Wake Forest University Health Sciences	Vitamin D and Genistein Inhibition of Prostate Growth	\$44,844
PC040996	Peterson	Blake	The Pennsylvania State University	Anticancer Inhibitors of AR-Mediated Gene Expression	\$349,778
PC041004	Reddy	Prem Veer	Henry Ford Health System	Role of Androgen Receptor in Progression of Prostate Cancer Cells from G1 into S Phase: New Potential Targets for Treatment of Disseminated Prostate Cancer	\$540,000
PC041013	Desprez	Pierre-Yves	California Pacific Medical Center	HLH Proteins in Prostate Cancer Cells	\$365,085

PC041024	Minev	Boris	University of California, San Diego	Nanoparticle-Based Vaccines for Immunotherapy of Prostate Cancer	\$570,000
PC041039	Kraft	Andrew	Medical University of South Carolina	Pim Protein Kinase-Levels Correlate with Prostate Tumor Growth and Chemo-Resistance-Potential Mechanism of Pim Action	\$569,781
PC041048	Chakrabarti	Ratna	University of Central Florida	Role of LIM Kinase 1 in Regulation of Growth and Invasiveness of Prostate Cancer Cells	\$536,250
PC041075	Yang	Li-Xi	California Pacific Medical Center Research Institute	Targeted Chemoradiosensitization of Prostate Cancer	\$485,742
PC041102	Klostergaard	Jim	University of Texas MD Anderson Cancer Center	Novel Anti-PSMA Antibody-Based Paclitaxel Copolymer Prodrugs for Intraprostatic Treatment of Localized Prostatic Carcinoma	\$566,250
PC041115	Koutcher	Jason	Sloan-Kettering Institute for Cancer Research	Non-Invasive Markers of Tumor Growth, Metastases, and Sensitivity to Anti-Neoplastic Therapy	\$631,873
PC041117	Manfredi	James	Mount Sinai School of Medicine	Restoration of Wild-Type Activity to Mutant p53 in Prostate Cancer: A Novel Therapeutic Approach	\$630,636
PC041123	Rafnar	Thorunn	Iceland Genomics Corporation	A Population Based Genetic Association Study on Prostate Cancer	\$468,750
PC041158	Nelson	Peter	Fred Hutchinson Cancer Research Center	Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis	\$635,810

New Investigator Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040118	Schmelz	Monika	University of Arizona	The Plasticity of Human Normal Prostate Glandular Homeostasis	\$281,250
PC040130	Kwee	Sandi	The Queen's Medical Center	Cancer Localization in the Prostate with F-18 Fluorocholine Positron Emission Tomography	\$391,430
PC040144	Franc	Benjamin	University of California, San Francisco	Novel Prostate Cancer Targeting Mechanism for Imaging with Positron Emission Tomography	\$279,738
PC040153	Aktas	Huseyin	Harvard Medical School	Molecular and Cellular Targets of n-3 Polyunsaturated Fatty Acids for Prostate Cancer Prevention	\$339,383
PC040255	Yoon	HoGeun	Baylor College of Medicine	The Role of Corepressor Complexes in an Androgen Receptor-Mediated Transcriptional Regulation	\$56,438
PC040312	Logan	Susan	New York University School of Medicine	Function of an Androgen Receptor Coactivator Regulated in Prostate Development and Prostate Cancer	\$380,083
PC040326	Kwabi-Addo	Bernard	Baylor College of Medicine, VAMC Research Ctr 151	Mechanisms Down-Regulating Sprouty1, a Growth Inhibitor in Prostate Cancer	\$338,625
PC040372	Kashina	Anna	University of Pennsylvania	Role of Protein Arginylation in Prostate Cancer	\$356,625
PC040413	Nevalainen	Marja	Georgetown University Medical Center	Transcription Factor Stat5 as a Therapeutic Target Protein for Prostate Cancer	\$349,200
PC040435	Lewis	Jason	Washington University in St. Louis	Delineating the Effects of Tumor Therapies on Prostate Cancer Using Small Animal Imaging Technologies	\$344,250
PC040440	Smiraglia	Dominic	Roswell Park Cancer Institute	Development of Candidate DNA Methylation Biomarkers in Recurrent Prostate Carcinoma	\$403,888
PC040484	Balaji	Kethandapatti	University of Nebraska Medical Center	MT 2A Phosphorylation by PKC Mu/PKD Influences Chemosensitivity to Cisplatin in Prostate Cancer	\$330,750
PC040506	Garzotto	Mark	Oregon Health and Science University	Cyclooxygenase-Targeted Prostate Cancer Prevention	\$282,510
PC040569	Lu	Qun	East Carolina University	Functions of (delta)-Catenin in Prostate Cancer	\$320,625
PC040570	Datta	Kaustubh	Mayo Clinic Rochester	Elucidation of the Molecular Mechanism Underlying Lymph Node Metastases in Prostate Cancer	\$326,475

PC040578	Wang	Ruoxiang	Emory University School of Medicine	Functional Characterization of a Novel Prostate-Specific Gene PrLZ in Prostate Cancer	\$344,250
PC040607	Matsuzawa	Shu-ichi	The Burnham Institute	The Role of Siah1-Induced Degradation of (beta)-Catenin in Androgen Receptor Signaling	\$429,750
PC040630	Lee	Yi-Fen	University of Rochester	To Investigate the Therapeutic Effects of the COX-2 Inhibitor NS-398 as a Single Agent, and in Combination with Vitamin D, in Vitro and in Vivo	\$353,907
PC040641	Xu	Bo	Louisiana State University Health Sciences Center	Interfering with DNA Damage Signals: Radiosensitizing Prostate Cancer Using Small Peptides	\$319,070
PC040685	Bacich	Dean	University of Pittsburgh	The Role of Prostate-Specific Membrane Antigen (PSMA) in Prostate Cancer Initiation and Progression	\$324,990
PC040753	von Bulow	Gotz-Ulrich	Indiana University School of Medicine	A Role for TACI in Prostate Neoplasia	\$338,625
PC040806	Olumi	Aria	Harvard Medical School/ Beth Israel Deaconess Medical Center	The Role of c-FLIP(L) in Regulating Apoptotic Pathways in Prostate Cancer	\$382,338
PC040972	Oelke	Mathias	Johns Hopkins University School of Medicine	Development of Antigen Presenting Cells for Adoptive Immunotherapy in Prostate Cancer	\$367,216
PC040985	Varghese	Susan	Massachusetts General Hospital	Systemic Oncolytic Cytokine HSV Therapy of Prostate Cancer	\$393,498
PC041053	Liu	Cheng	The Scripps Research Institute	Selective Infarction of Prostate Cancer	\$422,239
PC041122	Kridel	Steven	Wake Forest University Health Sciences	Inhibition of Fatty Acid Synthase in Prostate Cancer by Orlistat, a Novel Therapeutic	\$319,269
PC041126	Huang	Lan	University of California, Irvine	Proteomics of Nedd8 Pathway in Human Prostate Cancer	\$342,437

HBCU Undergraduate Collaborative Summer Training Program Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC041208	Yao	Yu-Dong	Stevens Institute of Technology	Test Bed Development for Detection and Diagnosis of Prostate Cancer via Internet and Wireless Communication Networks	\$200,000
PC041224	Price	Marva	Duke University	Partnering Research Involving Mentoring and Education (PRIME) in Prostate Cancer	\$199,890
PC041227	McDonnell	Timothy	The University of Texas M.D. Anderson Cancer Center	Texas Southern University (TSU) and the Graduate School of Biomedical Sciences (GSBS) Undergraduate Collaborative Training Program in Prostate Cancer	\$199,899

Health Disparity Training - Prostate Scholar Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040517	Mehra	Rohit	University of Michigan Medical School	Tissue Microarray Assessment of Novel Prostate Cancer Biomarkers AMACR and EZH2 and Immunologic Response to Them in African American and Caucasian Men	\$184,268

Physician Research Training Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040167	Spencer	Benjamin	University of California, Los Angeles	Quality-of-Care Indicators for Early-Stage Prostate Cancer	\$699,605
PC041206	Kao	Johnny	Mount Sinai School of Medicine, New York	(gamma) -H2AX Kinetics as a Molecular Predictor of Prostate Cancer Radiosensitivity and Screening Assay for the Development of Small Molecule Radiosensitizers	\$697,255
PC041210	Lee (Li)	Peng	New York University School of Medicine	Distinct Regulation of Prostate Cancer Growth by Two Isoforms of Androgen Receptor Coactivator ARA70 (alpha) and ARA70 (beta)	\$699,995
PC041214	Pavlovich	Christian	Johns Hopkins Bayview Medical Center	Prostate Cancer Detection by Molecular Urinalysis	\$647,688
PC041219	Guruli	Georgi	University of Medicine and Dentistry of New Jersey - New Jersey Medical School	Activation and Protection of Dendritic Cells in the Prostate Cancer Environment	\$699,234
PC041220	Rosenberg	Jonathan	University of California, San Francisco	Gene Expression Analysis of Circulating Hormone Refractory Prostate Cancer Micrometastases	\$560,000
PC041222	Walker	Jonathan	University of Arizona	Molecular Targeting of the PI3K/Akt Pathway to Prevent the Development Hormone Resistant Prostate Cancer	\$677,992
PC041223	Bermejo	Carlos	University of Texas Health Science Center at San Antonio	Common Variants as a Molecular Signature for Aggressive Prostate Cancer	\$699,385
PC041225	Banck	Michaela	Mount Sinai School of Medicine	Molecular Mechanisms of the KLF6 Tumor Suppressor in Prostate Cancer	\$549,452

Postdoctoral Traineeship Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
PC040009	Maggi	Leonard	Washington University	Role of the ARF Tumor Suppressor in Prostate Cancer	\$124,416
PC040020	Wang	Qianben	Dana-Farber Cancer Institute	Allele-Specific Androgen Receptor Coregulator Recruitment	\$125,000
PC040054	Whitehurst	Angelique	University of Texas-Southwestern Medical Center	The Role of RASSF1A in Prostate Cancer Initiation and Progression	\$123,075
PC040090	Toby	Garabet	Dana-Farber Cancer Institute	Chemical Genetics of 14-3-3 Regulation and Role in Tumor Development	\$125,000
PC040107	Williams	Simon	Johns Hopkins University	The Role of Enzymatically Active PSA in Prostate Cancer Pathobiology	\$125,000
PC040120	Moreno	Jacqueline	Stanford University	Vitamin D-Prostaglandin Interactions and Effects on Prostate Cancer	\$124,869
PC040129	Duza	Tasmia	The Burnham Institute	Targeting Organ Specific Prostate Cancer Metastases	\$125,000
PC040154	Jin	Ren	Vanderbilt University Medical Center	Investigating the Role of p57Kip2 in Prostate Cancer	\$125,000
PC040158	Solban	Nicolas	Massachusetts General Hospital	Optical Strategies for Studying Metastatic Mechanisms, Tumor Cell Detection and Treatment of Prostate Cancer	\$124,995
PC040159	Liberal	Vasco	The Scripps Research Institute	Dissection of the Effect of Cyclin E Deregulation in the Development and Progression of Prostate Cancer Using Mouse Models	\$125,000
PC040185	Chinnaiyan	Prakash	University of Wisconsin-Madison	Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deacetylase (HDAC) Inhibition in Prostate Cancer Cell Lines	\$150,000
PC040247	Qi	Yingchuan	University of California, San Diego	Androgen Receptor/Cofactor Exchange Complex in Prostate Cancer	\$125,000
PC040267	Odero-Marah	Valerie	Emory University School of Medicine	The Biology of Epithelial-Mesenchymal Transition in Prostate Cancer	\$125,000
PC040285	Wang	Xiaoju	Regents of the University of Michigan	Early Detection of Prostate Cancer by Profiling the Humoral Immune Response in Patients Using High Throughput Phage Epitope Microarray	\$125,000
PC040337	Zhang	Chu	University of Delaware	Function of Perlecan Domain I in Prostate Cancer	\$125,000

PC040369	Song	Jun	The Regents of the University of California	Tissue Specific Gene Silencing in Prostate Cancer Cells	\$123,500
PC040380	O'Mahony	Orla	Regents of the University of Michigan	Differential Mechanisms of Androgen Resistance	\$125,000
PC040393	Wilkinson	John	Regents of the University of Michigan	Role of the XIAP/AIF Axis in the Development and Progression of Prostate Cancer	\$125,000
PC040398	Rabinovsky	Rosalia	Dana Farber Cancer Institute	Identification and Validation of PTEN Complex-Associated Proteins	\$124,022
PC040416	Cloud King	Jennifer	University of California, Los Angeles	Understanding Hormone Receptor and Oncogene Crosstalk in Prostate Cancer	\$125,000
PC040429	Kan	Shih-hsin	University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School	The Role of Hoxb13 and Nkx3.1 in Prostate Development and Carcinogenesis	\$125,000
PC040452	Jiao	Jing	University of California, Los Angeles	Molecular Mechanism of Nkx3.1 Dereglulation and Its Function in Murine Pten Prostate Cancer Model	\$125,000
PC040458	Chowdhury	Subir	McMaster University	Role of Mitochondria in Prostate Cancer	\$106,470
PC040485	Yepuru	Murali	Baylor College of medicine	Vitamin D Receptor (VDR) Agonists: Inhibition of Prostate Tumor Growth, Angiogenesis, and Metastasis	\$125,000
PC040493	Mimeault	Murielle	University of Nebraska Medical Center	Novel Combinational Therapy Against Prostate Cancer	\$125,000
PC040499	Chen	Shaoyong	Beth Israel Deconess Medical Center/ Harvard Medical School	Regulation of AR and (beta)-Catenin Signaling by Pin1 in Prostate Cancer	\$125,000
PC040567	Kim	Dong	Vanderbilt University Medical Center	Molecular Profiling of Prostate Cancer to Determine Predictive Markers of Response to Radiation and Receptor Tyrosine Kinase Inhibitor Therapy	\$149,960
PC040568	Zhang	Zhuo	University of Alabama at Birmingham	MDM2 as a Target for Prostate Cancer Prevention and Therapy	\$125,000
PC040587	Veeramani	Suresh	University of Nebraska Medical Center	Role of Oxidative Stress in the Development of Androgen-Independence in Prostate Cancer Cells	\$125,000
PC040604	Zirong	Wang	New York Medical College	Identification of Resveratrol Targeting Proteins by Affinity Column-Linked Proteomics and Studies of Their Role in Prostate Cancer Progression	\$115,385
PC040616	Nonn	Larisa	Stanford University School of Medicine	Molecular Mechanism for Prostate Cancer Resistance to the Anti-Tumor Activity of Vitamin D	\$124,808

PC040638	Beroukhim	Rameen	Dana-Farber Cancer Institute	High-Resolution Mapping of Structural Mutations in Prostate Cancer with Single Nucleotide Polymorphism Arrays	\$149,743
PC040640	Gupta	Seema	Geisinger Clinic	Radio-Sensitizing Effects of Novel Histone De-Acetylase Inhibitors in Prostate Cancer	\$124,922
PC040643	Kaur	Ramneet	Beth Israel Deaconess Medical Center	Role of PAK6 in Prostate Cancer	\$125,000
PC040684	Choy	Grace	University of Texas M.D. Anderson Cancer Center	The Mitochondrial HSP60 Protein as a Prosurvival Molecule in Prostate Cancer Cells During Apoptosis Induction	\$124,993
PC040697	Mattie	Michael	University of California, San Francisco	Identification of MicroRNAs and Their Effects on Gene Expression in Prostate Cancer	\$83,071
PC040702	van Drogen	Audrey	Sidney Kimmel Cancer Center	The Role of hCDC4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer	\$125,000
PC040794	Yi	Ming	Sidney Kimmel Cancer Center	Immunotargeting Prostate Tumors	\$124,820
PC040800	Qian	Zheng (David)	Johns Hopkins University	Restoration of Transforming Growth Factor beta Signaling by Histone Deacetylase Inhibitors in Human Prostate Carcinoma	\$125,000
PC040833	Kim	Ki	University of Pittsburgh	Modulation of TRAIL Cytotoxicity by Amiloride in Prostate Cancer	\$125,000
PC040897	Navsariwala	Veda	University of Illinois at Chicago	Selenoproteins and Prostate Cancer	\$125,000
PC041067	Ai	Hua	Case Western Reserve University	Combined Radiation and (beta)-Lapachone Millirod Therapy for Prostate Tumors	\$125,000
PC041078	Garcia-Hernandez	Maria de la Luz	University of Southern California	Development of STEAP-Based Vaccines for the Treatment of Prostate Cancer	\$125,000
PC041112	Zhang	Liyang	Sloan-Kettering Institute for Cancer Research	Identification of Molecular Mechanisms Involved in the Androgen Receptor Gene Expression in Prostate Cancer	\$124,992

**Fiscal Year 2004 Prostate Cancer Research Program
Peer Reviewers**

Peer Reviewers	Degree	Institution/Affiliation
Abcouwer, Steve	Ph.D.	University of New Mexico School of Medicine
Ahaghotu, Chiledum	M.D.	Howard University Hospital
Ahmed, Khalil	Ph.D.	University of Minnesota & VA Medical Center
Ahmed, Mansoor	Ph.D.	University of Kentucky Medical Center
Angtuaco, Teresita	M.D.	University of Arkansas for Medical Sciences
Arlen, Philip	M.D.	National Institutes of Health, National Cancer Institute
Ayala, Gustavo	M.D.	Baylor College of Medicine
Bahnson, Robert	M.D.	Ohio State University College of Medicine
Banerjee, Debabrata	Ph.D.	University of Medicine and Dentistry of New Jersey
Banerjee, Partha	Ph.D.	Georgetown University Medical Center
Bar-Eli, Menashe	Ph.D.	University of Texas MD Anderson Cancer Center
Barlow, William	Ph.D.	Cancer Research and Biostatistics
Bartlett, Darrell		American Cancer Society
Batra, Surinder	Ph.D.	University of Nebraska Medical Center
Bayouth, John	Ph.D.	University of Texas Medical Branch at Galveston
Bennett, Gary	Ph.D.	Dana-Farber Cancer Institute/Harvard School of Public Health
Blaner, William	Ph.D.	Columbia University College of Physicians and Surgeons
Blank, Thomas		Hartford Hospital Support Group
Boothman, David	Ph.D.	Case Western Reserve University
Bova, G. Steven	M.D.	Johns Hopkins Hospital
Brach, Philip		WRAMC, US TOO
Braunhut, Susan	Ph.D.	University of Massachusetts, Lowell
Bridges, Kenneth	M.D.	Harvard Medical School
Briehl, Margaret	Ph.D.	University of Arizona
Bright, Robert	Ph.D.	Texas Tech University Health Sciences Center
Buatti, John	M.D.	University of Iowa Hospital and Clinics
Bublely, Glenn	M.D.	Harvard Institute of Medicine
Buettner, Garry	Ph.D.	The University of Iowa
Bushman, Wade	M.D., Ph.D.	Northwestern University School of Medicine
Butterfield, Lisa	Ph.D.	University of Pittsburgh
Buttyan, Ralph	Ph.D.	Columbia University

Peer Reviewers	Degree	Institution/Affiliation
Cairns, Paul	Ph.D.	Fox Chase Cancer Center
Campbell, Colin		US TOO! International
Caputi, Anthony		American Foundation for Urologic Disease
Cerhan, James	M.D., Ph.D.	Mayo Clinic College of Medicine
Chai, Karl	Ph.D.	University of Central Florida
Chatterjee, Bandana	Ph.D.	University of Texas Health Science Center at San Antonio
Chatterton, Robert	Ph.D.	Northwestern University Medical School
Chavez, Noel	Ph.D.	University of Illinois, Chicago
Chen, Ching-Shih	Ph.D.	Ohio State University
Chen, Xinbin	Ph.D.	University of Alabama, Birmingham
Chen, Yong	Ph.D.	Wake Forest University
Chin, Y. Eugene	M.D., Ph.D.	Brown University School of Medicine
Chrysogelos, Susan	Ph.D.	University of Michigan
Cidlowski, John	Ph.D.	NIEHS, NIH
Clark, Barbara	Ph.D.	University of Louisville
Cole, Jack	Ph.D.	Scientific Review Administrator
Collinge, William	Ph.D.	Collinge & Associates
Conti, Claudio	D.V.M., Ph.D.	University of Texas MD Anderson Cancer Center
Cooper, Carlton	Ph.D.	University of Delaware
Corey, Eva	Ph.D.	University of Washington
Cramer, Scott	Ph.D.	Wake Forest School of Medicine
Cryderman, Dale		American Cancer Society
Cryns, Vincent	M.D.	Northwestern University, Feinberg School of Medicine
Dahiya, Rajvir	Ph.D.	University of California, San Francisco/VAMC
Dai, Wei	Ph.D.	New York Medical College
Dainiak, Nicholas	M.D.	Bridgeport Hospital
Darpa, Peter	Ph.D.	Uniformed Services University of the Health Sciences
Davis, Nancy	M.D.	Medical College of Wisconsin
Day, Mark	Ph.D.	University of Michigan
De Carli, Harold		First State Prostate Cancer Support Group
DeJong, Kees		Prostate Cancer Networking Group of Greater Cincinnati
Denmeade, Samuel	M.D.	The Johns Hopkins School of Medicine
Dhir, Rajiv	M.D.	University of Pittsburgh
Diana, John	Ph.D.	Scientific Review Administrator

Peer Reviewers	Degree	Institution/Affiliation
DiRenzo, James	Ph.D.	Dartmouth Medical School
Dong, Jin-Tang	Ph.D.	Emory University, Winship Cancer Institute
Douglas, Joanne	Ph.D.	University of Alabama, Birmingham
Doxsey, Stephen	Ph.D.	University of Massachusetts Medical Center
Eaton, John	Ph.D.	J.G. Brown Cancer Center, University of Louisville
Ebbinghaus, Scot	M.D.	Arizona Cancer Center, University of Arizona
Edwards, Christopher	Ph.D.	Duke University Medical Center
Erhardt, Paul	Ph.D.	University of Toledo
Evans, Lemuel	Ph.D.	Scientific Review Administrator
Fidoten, Robert		US TOO! University of Pittsburgh Cancer Institute
Foster, Barbara	Ph.D.	Roswell Park Cancer Institute
Foster, Ken		US TOO! Los Robles Regional Medical Center
Fraizer, Gail	Ph.D.	Kent State University
Frankel, Carl		US TOO!
Franklin, Renty	Ph.D.	University of Maryland Dental School
Gabrilovich, Dmitry	M.D., Ph.D.	H. Lee Moffitt Cancer Center, University of South Florida
Ganapathi, Ram	Ph.D.	Cleveland Clinic Foundation
Gattoni-Celli, Sebastiano	M.D.	Medical University of South Carolina
Gelman, Irwin	Ph.D.	Roswell Park Cancer Institute
Gewirtz, David	Ph.D.	Virginia Commonwealth University, MCV Campus
Ghoda, Lucy	Ph.D.	Webb-Waring Institute for Cancer Aging and Ant, University of Colorado Health Science Center
Gius, David	M.D., Ph.D.	NIH Center for Cancer Research
Goins, William	Ph.D.	University of Pittsburgh School of Medicine
Goluboff, Erik	M.D.	Columbia-Presbyterian Medical Center
Goodman, Alan	Ph.D.	Scientific Review Administrator
Graham, Charles	Ph.D.	Queen's University
Gregor, Polly	Ph.D.	Memorial Sloan-Kettering Cancer Center
Griffith, Jeffrey	Ph.D.	Dept of Biochemistry and Molecular Biology, Univ of New Mexico School of Medicine
Grimley, Philip	M.D.	Uniformed Services University of the Health Sciences
Groelle, Eugene		PCA101
Gross, Alexander		American Cancer Society
Gulati, Jag	Ph.D.	Scientific Review Administrator
Gumerlock, Paul	Ph.D.	University of California Davis Cancer Center

Peer Reviewers	Degree	Institution/Affiliation
Gupta, Rishab	Ph.D.	John Wayne Cancer Institute
Hahn, Stephen	M.D.	University of Pennsylvania
Hahn, William	M.D., Ph.D.	Dana-Farber Cancer Institute
Hann, Stephen	Ph.D.	Vanderbilt University School of Medicine
Haut, Michael	M.D.	Pennsylvania Hospital
Hayward, Simon	Ph.D.	Vanderbilt University School of Medicine
Hedlund, Dalva		American Cancer Society
Helman, Sandy	Ph.D.	Scientific Review Administrator
Hemstreet, III, George	M.D., Ph.D.	Nebraska Medical Center
Henning, Susanne	Ph.D.	University of California, Los Angeles
Heston, Warren	Ph.D.	Cleveland Clinic Foundation, Lerner Research Institute
Hickey, Robert	Ph.D.	Indiana University School of Medicine
Holt, Shawn	Ph.D.	Virginia Commonwealth University School of Medicine
Howard, Steve	Ph.D.	University of Wisconsin-Madison
Hsieh, Jer-Tsong	Ph.D.	University of Texas Southwestern Medical Center at Dallas
Hu, Guo-Fu	Ph.D.	Harvard Medical School
Hu, Mickey	Ph.D.	University of Texas MD Anderson Cancer Center
Huda, Amir	Ph.D.	California State University, Fresno
Ittmann, Michael	M.D., Ph.D.	Houston VAMC
Jarrard, David	M.D.	University of Wisconsin
Jeng, Meei-Huey	Ph.D.	Indiana University
Johnson, Michael	Ph.D.	Georgetown University, Lombardi Cancer Center
Jones, David		US TOO! International
Josephs, Milton		US TOO! PC Support Group
Junker, Lawrence		US TOO! International
Kan-Mitchell, June	Ph.D.	Karmanos Cancer Institute
Kao, Chinghai	Ph.D.	Indiana University
Kaplan, Joel		American Cancer Society
Kasper, Susan	Ph.D.	Vanderbilt University Medical Center
Kazanietz, Marcelo	Ph.D.	University of Pennsylvania School of Medicine
Kazmi, Salman	M.D.	George Washington Medical Center
Keller, Evan	D.V.M., Ph.D.	University of Michigan
Keller, Jonathan	Ph.D.	National Cancer Institute-Frederick
Keri, Ruth	Ph.D.	Case Western Reserve University

Peer Reviewers	Degree	Institution/Affiliation
Kern, Francis	Ph.D.	Lexicon Genetics, Inc.
Khan, Mohamed	M.D., Ph.D.	University of Michigan
Kilbridge, Kerry	M.D.	University of Virginia
Kim, Hyeong-Reh	Ph.D.	Wayne State University
Kinch, Michael	Ph.D.	MedImmune Inc.
Kirlin, Ward	Ph.D.	Morehouse School of Medicine
Kiseda, James		American Cancer Society
Knudsen, Beatrice	M.D., Ph.D.	Fred Hutchinson Cancer Research Center
Kohlmeier, Hermann	M.D., Ph.D., D.Sc.	University of North Carolina-Chapel Hill
Kumar, M. Vijay	Ph.D.	Medical College of Georgia
Kung, Hsing-Jien	Ph.D.	University of California-Davis Cancer Center
Kurt, Robert	Ph.D.	Lafayette College
Kwak-Kim, Joanne	M.D.	Rosalind Franklin University of Medicine and Science
Kyprianou, Natasha	Ph.D.	University of Kentucky College of Medicine
Lafrado, Louis	Ph.D.	L&D Associates Consulting Group
Lamb, Dolores	Ph.D.	Baylor College of Medicine
Lamm, Marilyn	Ph.D.	Northwestern University Feinberg School of Medicine
Lamph, William	Ph.D.	Ligand Pharmaceuticals Incorporated
Lange, Carol	Ph.D.	University of Minnesota Cancer Center
Larner, James	M.D.	University of Virginia
Leach, Fredrick	M.D., Ph.D.	Baylor College of Medicine
Leach, Robin	Ph.D.	University of Texas Health Science Center
Lee, Chung	Ph.D.	Northwestern University Medical School
Lee, Eva	Ph.D.	Georgia Institute of Technology
Lee, Sam	Ph.D.	Harvard Institutes of Medicine/Beth Israel Deaconess Medical Center
Levine, Alice	M.D.	Mount Sinai School of Medicine
Lewis, Lionel	M.D.	Dartmouth College
Li, Zuofeng	D.Sc.	Washington University School of Medicine
Lillard, Jr., James	Ph.D., M.B.A.	Morehouse School of Medicine
Lin, Young	D.V.M., Ph.D.	Ohio State University
Lingrel, Jerry	Ph.D.	University of Cincinnati College of Medicine
Lipkus, Isaac	Ph.D.	Duke University Medical Center
Locker, Joseph	M.D., Ph.D.	Albert Einstein College of Medicine

Peer Reviewers	Degree	Institution/Affiliation
Lockwood, John		US TOO! of Oconee
Lokeshwar, Balakrishna	Ph.D.	University of Miami School of Medicine
Lokeshwar, Vinata	Ph.D.	University of Miami School of Medicine
Lopaczynski, Wlodek	M.D., Ph.D.	BBI Biotech Research Laboratories
Lorenzi, Matthew	Ph.D.	Bristol-Myers Squibb
Lu, Michael	Ph.D.	Brigham and Women's Hospital
Lubaroff, David	Ph.D.	University of Iowa
Lum, Clark	Ph.D.	Scientific Review Administrator
Madalengoitia, Jose	Ph.D.	University of Vermont
Mandelson, Margaret	Ph.D., M.P.H.	Center for Health Studies, Group Health Cooperative of Puget Sound
Manfredi, James	Ph.D.	Ruttenberg Cancer Center, Mount Sinai School of Medicine
Mannarino, Maria	M.D.	Scientific Review Administrator
Mantulin, William	Ph.D.	University of Illinois at Urbana-Champaign
Marcus, Aaron	M.D.	Weill Medical College-Cornell University
Marengo, Susan Ruth	Ph.D.	Case Western Reserve University
Masters, Joseph		US TOO! of Western New York
McCarthy, James	Ph.D.	University of Minnesota
McConkey, David	Ph.D.	University of Texas MD Anderson Cancer Center
McDonnell, Timothy	M.D., Ph.D.	University of Texas MD Anderson Cancer Center
McLeskey, Sandra	Ph.D.	University of Maryland Baltimore
Mehta, Parmender	Ph.D.	University of Nebraska Medical Center
Mehta, Rajendra	Ph.D.	University of Illinois
Melamed, Jonathan	M.D.	New York University School of Medicine
Merkle, Carrie	Ph.D., RN, FAAN	University of Arizona
Meruelo, Daniel	Ph.D.	New York University Medical Center
Miele, Lucio	M.D., Ph.D.	University of Illinois at Chicago
Mikkelsen, Ross	Ph.D.	Virginia Commonwealth University
Moadel, Renee	M.D.	Montefiore Medical Center, Albert Einstein College of Medicine
Mohler, James	M.D.	Roswell Park Cancer Institute
Morris, Donald	M.D., Ph.D.	Tom Baker Cancer Center, University of Calgary
Morris, Patricia	Ph.D.	The Rockefeller University
Mukherji, Bijay	M.D.	University of Connecticut
Mukhtar, Hasan	Ph.D.	University of Wisconsin

Peer Reviewers	Degree	Institution/Affiliation
Mulhern, Sally	Ph.D.	Scientific Review Administrator
Nalcioglu, Orhan	Ph.D.	University of California
Narayan, Satya	Ph.D.	University of Florida
Navone, Nora	M.D., Ph.D.	University of Texas MD Anderson Cancer Center
Neel, Robert		Prostate Cancer Support Association of New Mexico
Nelson, Colleen	Ph.D.	University of British Columbia, Jack Bell Research Centre
Nelson, Peter	M.D.	University of Washington School of Medicine, Fred Hutchinson Cancer Research Center
Nishimura, Michael	Ph.D.	University of Chicago Medical Center
Noguchi, Constance	Ph.D.	NIDDK/National Institutes of Health
Nutter, John	Ph.D.	Scientific Review Administrator
Oh, William	M.D.	Dana Farber Cancer Institute
O'Hara, Dennis		Man to Man, American Cancer Society
Ojong-Ntui, Martin	M.D.	George Washington University Hospital
Olsen, Phillip		US TOO! International
Olumi, Aria	M.D.	Beth Israel Deaconess Medical Center/Harvard Medical School
Ornstein, David	M.D.	University of California, Irvine
O'Rourke, Maureen	Ph.D.	University of North Carolina, Greensboro
Ove, Peter	Ph.D.	Scientific Review Administrator
Palmer, Gordon		Wheeling Hospital and US TOO International
Pardo, Francisco	M.D.	University of California-San Diego
Parker, Alexander	Ph.D.	Mayo Clinic
Peehl, Donna	Ph.D.	Stanford University Medical Center
Perales, Miguel-Angel	M.D.	Memorial Sloan Kettering Cancer Center
Perez-Stable, Carlos	Ph.D.	Miami VA Medical Center
Peschel, Richard	M.D., Ph.D.	Yale University School of Medicine
Pins, Michael	M.D.	Northwestern University
Pizzorno, Giuseppe	Ph.D., Pharm.D.	Yale University School of Medicine
Porter, Paul		US TOO
Quinn, John		Beverly Hospital
Quinn, Thomas	Ph.D.	University of Missouri
Rangnekar, Vivek	Ph.D.	University of Kentucky
Rayford, Walter	M.D., Ph.D.	Louisiana State University-New Orleans
Reiter, Robert	M.D.	University of California, Los Angeles School of Medicine

Peer Reviewers	Degree	Institution/Affiliation
Richardson, Robert		Sun Health Research Institute
Riese, David	Ph.D.	Purdue University
Rinker-Schaeffer, Carrie	Ph.D.	University of Chicago
Roberts, Jr. Charles	Ph.D.	Oregon Health and Science University
Rodgers, Charles	Ph.D.	Scientific Review Administrator
Rodriguez, Ronald	M.D., Ph.D.	Brady Urological Institute, Johns Hopkins Medical Institute
Rookey, Ernest		American Cancer Society
Rosenberg, Harry		US TOO Prostate Cancer-George Washington
Ross, Jeffrey	M.D.	McArdle Laboratory
Rubin, Charles		Southern Arizona Prostate Cancer Support
Rui, Hallgeir	M.D., Ph.D.	Georgetown University, Lombardi Cancer Center
Sadar, Marianne	Ph.D.	British Columbia Cancer Agency
Sakr, Wael	M.D.	Wayne State University School of Medicine
Sande, Brad		Olean Man-to-Man, Prostate Cancer Education and Support Group
Sandeen, William		Southern Nevada Cancer Research Foundation
Sanderson, Maureen	Ph.D.	University of Texas
Sang, Qing-Xiang	Ph.D.	Florida State University
Sarkar, Fazlul	Ph.D.	Wayne State University School of Medicine
Sartor, Oliver	M.D.	Louisiana State University Medical School
Scanlan, William		American Cancer Society
Schlyer, David	Ph.D.	Brookhaven National Laboratory
Schneider, Barbara	Ph.D.	Louisiana State University Health Sciences Center
Sens, Donald	Ph.D.	University of North Dakota, School of Medicine and Health Sciences
Shah, Girish	Ph.D.	University of Louisiana
Shain, Sydney	Ph.D.	University of Texas Health Science Center
Shaw, Chris	Ph.D.	Georgia Institute of Technology
Shekhar, Malathy	Ph.D.	Breast Cancer Program, Karmanos Cancer Institute
Sherry, Richard	M.D.	National Cancer Institute, National Institutes of Health
Shi, Yufang	Ph.D.	Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey
Sholes, Westley		California Prostate Cancer Coalition
Showalter, Paul		South Shore Hospital Prostate Support Group
Signoretti, Sabina	M.D.	Brigham and Women's Hospital, Harvard Medical School
Sikes, Robert	Ph.D.	University of Delaware

Peer Reviewers	Degree	Institution/Affiliation
Silva, Corinne	Ph.D.	University of Virginia Medical School
Simpson, Melanie	Ph.D.	University of Nebraska Lincoln
Singh, Rakesh	Ph.D.	University of Nebraska Medical Center
Skapek, Stephen	M.D.	St. Jude Children's Research Hospital
Skramstad, Gary		US TOO, St Cloud
Sloboda, Walter	M.A.	Scientific Review Administrator
Slovin, Susan	M.D., Ph.D.	Memorial Sloan Kettering Cancer Center
Smith, Allen	M.S.	Scientific Review Administrator
Spielmann, H. Peter	Ph.D.	University of Kentucky
Sproat, William		US TOO! International
Stamler, Arthur		US TOO of Greenville South Carolina
Stanford, Janet	Ph.D.	Fred Hutchinson Cancer Research Center
Stevens, Craig	M.D., Ph.D.	University of Texas MD Anderson Cancer Center
Stewart, Juarine	Ph.D.	Clark Atlanta University
Strom, Sara	Ph.D.	University of Texas MD Anderson Cancer Center
Sufrin, Gerald	M.D.	State University of New York at Buffalo
Sun, LuZhe	Ph.D.	University of Texas Health Science Center
Sun, Zijie	Ph.D.	Stanford University School of Medicine
Swallen, Thomas		Humphrey Cancer Institute
Swanson, Steven	Ph.D.	University of Illinois at Chicago
Tang, Dean	M.D., Ph.D.	University of Texas MD Anderson Cancer Center
Thomas, Peter	Ph.D.	Boston University School of Medicine
Thompson, E. Aubrey	Ph.D.	Cancer Research, Mayo Clinic
Thorburn, Andrew	Ph.D.	Wake Forest University School of Medicine
Tiwari, Raj	Ph.D.	New York Medical College
Totta, Paul		Poughkeepsie Man-to-Man (American Cancer)
Trevor, Katrina	Ph.D.	Arizona Cancer Center
Turley, Eva	Ph.D.	London Regional Cancer Centre
Turner, Timothy	Ph.D.	Tuskegee University
Tuszynski, George	Ph.D.	Temple University
Tycko, Benjamin	M.D., Ph.D.	Columbia University
Uchio, Edward	M.D.	Yale University School of Medicine
Umbreit, Jay	M.D., Ph.D.	Emory University, Winship Cancer Institute
Velicer, Wayne	Ph.D.	Cancer Prevention Research Center, University of Rhode Island

Peer Reviewers	Degree	Institution/Affiliation
Vessella, Robert	Ph.D.	University of Washington Medical Center
Vincent, Dawn	Ph.D., M.P.H.	Scientific Review Administrator
Walsh, Raymond		WRAMC US TOO Support Group
Wang, Shaomeng	Ph.D.	University of Michigan
Ware, Joy	Ph.D.	Virginia Commonwealth University School of Medicine
Weber, Christian	M.D.	Boston University School of Medicine
Weber, Georg	M.D., Ph.D.	University of Cincinnati Medical Center
Weigel, Nancy	Ph.D.	Baylor College of Medicine
Welch, Danny	Ph.D.	University of Alabama, Birmingham
Welsh, JoEllen	Ph.D.	University of Notre Dame
Whiting, Bruce	Ph.D.	Washington University School of Medicine
Williams, Briana	Ph.D.	Louisiana State University Health Sciences Center
Williams, DeWitt		Johns Hopkins University
Wu, T.C.	M.D., Ph.D.	Johns Hopkins University School of Medicine
Wynne, Burton		Brother to Brother
Xie, Wen	M.D., Ph.D.	University of Pittsburgh
Yao, Yin	Ph.D.	John Hopkins School of Public Health
Yen, Andrew	Ph.D.	Cornell University
Youngson, James		US TOO! International
Zebovitz, Eugene	Ph.D.	Scientific Review Administrator
Zhang, Jian-Ting	Ph.D.	Indiana University School of Medicine
Zhang, Ming	Ph.D.	Baylor College of Medicine
Zhang, Ruiwen	M.D., Ph.D.	University of Alabama, Birmingham
Zimmer, Stephen	Ph.D.	Markey Cancer Center, University of Kentucky
Zwicker, Robert	Ph.D.	University of Kentucky Medical Center

**Fiscal Year 2004 Prostate Cancer Research Program
Integration Panel (IP) Members**

IP Members	Degree	Institution/Affiliation
Carey, Thomas	Ph.D.	University of Michigan Comprehensive Cancer Center
deKernion, Jean	M.D.	University of California, Los Angeles
Dreicer, Robert	M.D.	The Cleveland Clinic Foundation
Lieberman, Ronald	M.D.	National Cancer Institute
Liebert, Monica	Ph.D.	American Urological Association
Miller, Donald	M.D., Ph.D.	James Graham Brown Cancer Center, University of Louisville
Prins, Gail	Ph.D.	University of Illinois at Chicago
Ratliff, Timothy	Ph.D.	University of Iowa
Roach, Mack III	M.D.	University of California, San Francisco
Simons, Virgil		The Prostate Net
Smith, Jr., Joseph	M.D.	Vanderbilt University Medical Center
Soule, Howard	Ph.D.	Knowledge Universe Health and Wellness
Van Auken, Wendell	MBA	Mayfield Partners
Vogelzang, Nicholas	M.D.	Nevada Cancer Institute
Waldman, Frederic	M.D., Ph.D.	University of California at San Francisco

**Fiscal Year 2004 Prostate Cancer Research Program
Ad Hoc Reviewers**

Ad Hoc Reviewers	Degree	Institution/Affiliation
Chinnaiyan, Arul	M.D.	University of Michigan
Cooney, Kathleen	M.D.	University of Michigan
Figg, William	Pharm.D.	National Cancer Institute
Freeman, Michael	M.D.	Children's Hospital Boston
Green, Jeffrey	M.D.	National Cancer Institute
Ho, Reginald	M.D.	University of Hawaii at Manoa
Robins, Diane	Ph.D.	University of Michigan
Sandler, Howard	M.D.	University of Michigan
Sholes, Westley		California Prostate Cancer Coalition and Brother-to-Brother Associates

Glossary of Terms

Clinical Trial Development Award: The PCRP funds Clinical Trials at two levels. The Clinical Trial Award, which is not offered until FY05, will provide for the rapid execution of novel patient-oriented research in a Phase I, Phase I/II, or Phase II clinical trial that has the potential to significantly impact the treatment, diagnosis, detection, or prevention of prostate cancer. The FY04 Clinical Trial Development Award is intended to provide support to establish the necessary collaborations and develop clinical protocols to provide a foundation for investigator-initiated clinical trials. The goal of these awards is to provide a foundation for the rapid execution of Phase I or Phase II clinical trial(s) that will have a major impact on the treatment, diagnosis, detection, or prevention of prostate cancer. As such, they should focus on new interventions and not on the refinements of existing interventions (e.g., optimizing timing or dosage regimens). Awardees of the Clinical Trial Development Award are required to submit a proposal to the FY05 Clinical Trial Award. *N.B.*, Unlike other award mechanisms, the Clinical Trial Development Award proposals receive a single level of review by the PCRP Integration Panel.

Exploration – Hypothesis Development Award: The intent of the Exploration – Hypothesis Development Award is to provide funds to support initial exploration of innovative, untested, and potentially groundbreaking concepts in prostate cancer. Exploration – Hypothesis Development Awards should (but are not required to) precede the articulation of a hypothesis or may provide the scientific rationale upon which a new hypothesis can be based. The award is designed to provide investigators with the opportunity to pursue serendipitous observations. The Exploration – Hypothesis Development Award is not intended to support ongoing work; therefore, the existence of preliminary data suggests that the research would be more appropriately submitted to a different award mechanism. Successfully completed Exploration – Hypothesis Development Awards are expected to lead to high-risk, potentially high-gain future research endeavors for this and other funding agencies. Projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b)(4)¹.

Exploration – Resource Development Award: The intent of the Exploration – Resource Development Award is to support product-driven research aimed at developing critical resources needed to advance prostate cancer research. These resources may include, but are not limited to, development of animal models, cell lines, and reagents. The award also will support studies whose purpose is to develop or refine analytical or experimental methodologies and to discover, develop, or screen new or existing therapeutics. Due to the developmental nature of this award, preliminary data are not required, but may be included if available, to address the feasibility of the resource to be developed. In either case, Exploration – Resource Development Award proposals must apply a sound scientific rationale and logical reasoning based on existing knowledge to the development of the proposed product. Projects involving human subjects or

¹Title 32, Code of Federal Regulations, Part 219, Section 101(b)(4). Research involving collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, is considered to be exempt under 32 CFR 219.101(b)(4).

specimens will not be supported unless they are exempt under 32 CFR 219.101(b)(4) or eligible for expedited review (45 CFR 46.110, 21 CFR 56.110)²

HBCU³ Collaborative Partnership Award: The intent of the HBCU Collaborative Partnership Award is to intensify the commitment of the prostate cancer research community to investigate the disparate burden of prostate cancer in African American men. To effectively address this issue, these awards are directed at HBCU as a means to increase the number of HBCU scientists who are trained as prostate cancer researchers. This award is designed to establish stable, long-term partnerships between an applicant HBCU and a collaborating non-HBCU institution to (1) provide mentorship and collaborative research opportunities for HBCU scientists, clinicians, and trainees; (2) develop, promote, and sustain independent, competitive research and training programs at the HBCU; and (3) increase the number of HBCU investigators focused on prostate cancer research. Although the applicant and proposal submission must be from an HBCU, a strong institutional commitment must be demonstrated by both partners. Established investigators from collaborating institutions must have a strong record of funding and achievement in prostate cancer research.

HBCU Undergraduate Collaborative Summer Training Program Award: The intent of the HBCU Undergraduate Collaborative Summer Training Program Award is to establish summer prostate cancer training programs at host institutions that will provide meaningful prostate cancer research experiences for undergraduate students enrolled at HBCU. A goal of the HBCU Collaborative Summer Training Program Award is to establish a relationship between the host institution and HBCU that will lead to attracting talented undergraduate students into careers that focus on prostate cancer research. It is anticipated that these awards will provide educational and training opportunities for undergraduate students at an important career decision-making point.

Health Disparity Research – Prostate Scholar Award: The intent of the Health Disparity Research – Prostate Scholar Award is intended to encourage investigators at assistant professor level or equivalent to focus their research efforts on the disparate burden of prostate cancer in African Americans. These awards will require the active involvement of a collaborator who is an established prostate cancer researcher. The ultimate goal of these awards is to resolve the disparity in prostate cancer incidence, morbidity, and mortality between African Americans and other ethnic groups. The proposal must explicitly express how the proposed research is related to a health disparity issue.

Health Disparity Training – Prostate Scholar Award: The intent of the Health Disparity Training – Prostate Scholar Award is intended to provide investigators in the **early stages** of their careers with training opportunities (under the guidance of a designated mentor) that focus on the disparate burden of prostate cancer in African Americans. The ultimate goal of these awards is to resolve the disparity in prostate cancer incidence, morbidity, and mortality between African Americans and other ethnic groups. The proposal must explicitly express how the proposed research is related to a health disparity issue. Under this award mechanism,

²For additional information, refer to the U.S. Department of Health and Human Services' Office of Human Research Protection website at <http://www.hhs.gov/ohrp>.

³Historically Black Colleges and Universities.

investigators may apply for Predoctoral Traineeships, Postdoctoral Traineeships, or Postresidency Traineeships.

Idea Development Award: The intent of the Idea Development Award is to encourage innovative approaches to prostate cancer research from established prostate cancer investigators and those investigators who are at the assistant professor level or equivalent who want to move into the prostate cancer field. Idea Development Award research should represent the start of something new, creating or introducing a unique or unusual approach to the study of prostate cancer. This research may represent a new paradigm, challenge existing paradigms, or look at an existing problem from a new perspective. All Idea Development proposals must include preliminary data.

New Investigator Award: The intent of the New Investigator Award is to support innovative ideas and technology from investigators in the early phases of their careers (within 6 years of their last fellowship or postdoctoral position). The applicant must be an independent investigator with access to appropriate research facilities and may not have received nonmentored funding exceeding \$100,000 in aggregate as a Principal Investigator (PI) from extramural sources. Proposals are not required to have preliminary data. Although this research is inherently risky and does not require preliminary data, these proposals should be based on a sound scientific rationale that is established through logical reasoning and/or a critical review and analysis of the literature.

Physician Research Training Award: The intent of the Physician Research Training Award is to provide a mentored training experience that will prepare physicians who are in the last year of graduate medical education or fellowships, or within the first 3 years of their appointment as an assistant professor or equivalent, for an independent career in prostate cancer research. A training program appropriate to the area of study (basic, translational, or population-based sciences) of the Principal Investigator (PI) must be part of the application; coursework and/or seminars in key areas such as statistics, bioethics, and/or relevant basic science disciplines within his or her area of research interest also may be included. Aggressive protection of the PI's time (minimum of 60% effort) for research also is provided through the award. A mentor with an established research program in prostate cancer research must be involved with the PI's training.

Postdoctoral Traineeship Award: The intent of the Postdoctoral Traineeship Award is to enable recent doctoral degree graduates with limited postdoctoral experience (i.e., 3 years or less at the time of proposal submission) either to extend ongoing research related to prostate cancer or to broaden the scope of their research to include work relevant to prostate cancer under the guidance of a designated mentor. The focus of these awards is on the applicant, the mentor, and the training environment. Eligible applicants must have successfully defended a doctoral thesis and completed all academic requirements at the time of award negotiation.